Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed testosterone therapy in transgender men
ACTRN12621000716864Phase 4Completed
- Sponsor
- University of Melbourne
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of testosterone and testosterone undecanoate in gender dysphoria (GD) (2 arms), sponsored by University of Melbourne. Primary endpoint: Symptoms of gender dysphoria. Started Nov 2021; status: completed.
02
Drugs
testosteronetestosterone undecanoate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on ACTRN12621000716864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000716864.